Family Medicine

This is the first and only FDA-approved cysteamine eye drop formulation, which is self-applied 4 times daily during waking hours.

Approximately 50% of patients with a mTBI who experience fatigue or sleep-wake disturbances 2 weeks following the injury continue to have problems at the 3 month mark.

An expert discusses ALKS 3831, a potential new treatment that demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

Patients impacted by pruritus were more depressed and anxious than a comparison control group.

J. John Mann, MD, discusses findings in a new study that uncovers the mechanisms behind Ketamine's antidepressant effect.

The potential new treatment has demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

J. John Mann, MD, compares esketamine nasal spray to intravenous administration and explains the drawbacks of the newly approved treatment method for MDD.

New data shows ischemic heart disease mortality decline has decelerated in recent years—while other heart disease subtypes have reversed course.

J. John Mann, MD, gives a brief overview of where we are now in treatment of major depressive disorder.

Genetic and environmental liability were linked to poorer mental health in a cohort of more than 6000 individuals based in the Netherlands.

Join us tomorrow for an informative discussion on CDC guidance and insights from medical experts on navigating a way back to in-school learning.

Categorizing baseline SCr as the median value over the preadmission period could be the least biased estimate of the baseline renal function.

Satralizumab represents only the second targeted treatment for NMOSD and the first cleared for at-home administration.

Investigators find study drug was well-tolerated with no new safety concerns.

A number of new modifiable risk factors for depression were identified including confiding in others, time spent watching television, and daytime napping.

SalivaDirect eliminates the need for nucleic acid extraction kits, enhancing the potential capacity for testing.

The degree of photoreceptor degeneration outside of regions of retinal pigment epithelium atrophy varied substantially between eyes with AMD.

From immunity building to plasma research, a look at some lesser efficient practices adopted or proposed during the pandemic.

A gastroenterologist discusses some of the findings regarding COVID-19 and gastrointestinal symptoms.

Less than 1% of nearly 500,000 hospitalized patients required kidney replacement therapy.

REGENXBIO also announced the scheduling of a phase 2 trial testing RGX-314 for wet AMD.

The risk of depression or clinically relevant depressive symptoms did not significantly differ between a group taking Vitamin D and a group taking a placebo.

In a comparison with manual human grading, investigators find machine learning model produced no statically significant differences in Dice coefficients.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

A team of researchers have added 3 new modifiable risk factors to a list of 9 known factors that increase the risk of developing dementia.